Ectopic fat and cardiovascular disease: What is the link?

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 7, 2010, Pages 481-490

  Gastaldelli, A ^a   Basta, G ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Cardiovascular disease; Epicardial fat; NAFLD non alcoholic fatty liver disease; Visceral fat

Indexed keywords

EID: 77955571859     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.05.005     Document Type: Short Survey

References (104)

1. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096.
2. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20-34.
3. Larsson B., Svardsudd K., Welin L., Wilhelmsen L., Bjorntorp P., Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984, 288:1401-1404.
4. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006, 2:335-348.
5. Gastaldelli A., Cusi K., Pettiti M., Hardies J., Miyazaki Y., Berria R., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133:496-506.
6. Kotronen A., Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
7. Iacobellis G., Ribaudo M.C., Assael F., Vecci E., Tiberti C., Zappaterreno A., et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003, 88:5163-5168.
8. Sironi A.M., Gastaldelli A., Mari A., Ciociaro D., Positano V., Buzzigoli E., et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004, 44:127-133.
9. Perseghin G., Lattuada G., De Cobelli F., Esposito A., Belloni E., Ntali G., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47:51-58.
10. Hwang J.H., Stein D.T., Barzilai N., Cui M.H., Tonelli J., Kishore P., et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 2007, 293:E1663-E1669.
11. Ferrannini E., Sironi A.M., Iozzo P., Gastaldelli A. Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk. Eur Heart J Suppl 2008, 10:B4-B10.
12. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 21:697-738.
13. Jensen M.D. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93:S57-S63.
14. Gastaldelli A., Miyazaki Y., Pettiti M., Buzzigoli E., Mahankali S., Ferrannini E., et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 2004, 89:3914-3921.
15. Kankaanpaa M., Lehto H.R., Parkka J.P., Komu M., Viljanen A., Ferrannini E., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91:4689-4695.
16. Mahabadi A.A., Massaro J.M., Rosito G.A., Levy D., Murabito J.M., Wolf P.A., et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009, 30:850-856.
17. Iacobellis G., Assael F., Ribaudo M.C., Zappaterreno A., Alessi G., Di Mario U., et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003, 11:304-310.
18. Sacks H.S., Fain J.N. Human epicardial adipose tissue: a review. Am Heart J 2007, 153:907-917.
19. Iozzo P., Lautamaki R., Borra R., Lehto H.R., Bucci M., Viljanen A., et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009, 94:4472-4482.
20. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005, 90:3498-3504.
21. Guerrero R., Vega G.L., Grundy S.M., Browning J.D. Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 2009, 49:791-801.
22. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999, 48:1600-1606.
23. Moro C., Bajpeyi S., Smith S.R. Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity. Am J Physiol Endocrinol Metab 2008, 294:E203-E213.
24. Despres J.P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
25. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
26. Dagenais G.R., Yi Q., Mann J.F., Bosch J., Pogue J., Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005, 149:54-60.
27. Lautamaki R., Borra R., Iozzo P., Komu M., Lehtimaki T., Salmi M., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291:E282-E290.
28. Lamb H.J., Smit J.W., van der Meer R.W., Hammer S., Doornbos J., de Roos A., et al. Metabolic MRI of myocardial and hepatic triglyceride content in response to nutritional interventions. Curr Opin Clin Nutr Metab Care 2008, 11:573-579.
29. Gastaldelli A., Kozakova M., Hojlund K., Flyvbjerg A., Favuzzi A., Mitrakou A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
30. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
31. Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006, 43:1145-1151.
32. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642.
33. Targher G., Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191:235-240.
34. Targher G., Bertolini L., Padovani R., Poli F., Scala L., Zenari L., et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006, 29:55-60.
35. Volzke H., Robinson D.M., Kleine V., Deutscher R., Hoffmann W., Ludemann J., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005, 11:1848-1853.
36. Brea A., Mosquera D., Martin E., Arizti A., Cordero J.L., Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005, 25:1045-1050.
37. Schindhelm R.K., Dekker J.M., Nijpels G., Bouter L.M., Stehouwer C.D., Heine R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191:391-396.
38. Aygun C., Kocaman O., Sahin T., Uraz S., Eminler A.T., Celebi A., et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2007.
39. Iacobellis G., Corradi D., Sharma A.M. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005, 2:536-543.
40. Djaberi R., Schuijf J.D., van Werkhoven J.M., Nucifora G., Jukema J.W., Bax J.J. Relation of epicardial adipose tissue to coronary atherosclerosis. Am J Cardiol 2008, 102:1602-1607.
41. Taguchi R., Takasu J., Itani Y., Yamamoto R., Yokoyama K., Watanabe S., et al. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis 2001, 157:203-209.
42. Ding J., Kritchevsky S.B., Harris T.B., Burke G.L., Detrano R.C., Szklo M., et al. Multi-ethnic study of A: the association of pericardial fat with calcified coronary plaque. Obes (Silver Spring) 2008, 16:1914-1919.
43. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. Circ J 2009, 73:27-34.
44. Sironi A.M., Pingitore A., Ghione S., De Marchi D., Scattini B., Positano V., et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension 2008, 51:282-288.
45. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
46. Tuunanen H., Engblom E., Naum A., Scheinin M., Nagren K., Airaksinen J., et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006, 12:644-652.
47. Neglia D., De Caterina A., Marraccini P., Natali A., Ciardetti M., Vecoli C., et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007, 293:H3270-H3278.
48. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784-1789.
49. Fox C.S., Massaro J.M., Hoffmann U., Pou K.M., Maurovich-Horvat P., Liu C.Y., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39-48.
50. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
51. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
52. Rajala M.W., Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
53. Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264-280.
54. Iacobellis G., di Gioia C.R., Cotesta D., Petramala L., Travaglini C., De Santis V., et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res 2009, 41:227-231.
55. Bertolani C., Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008, 15:91-101.
56. Bays H., Mandarino L., DeFronzo R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463-478.
57. Jain S.H., Massaro J.M., Hoffmann U., Rosito G.A., Vasan R.S., Raji A., et al. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study. Diabetes Care 2009, 32:903-908.
58. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277:25863-25866.
59. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
60. Combs T.P., Pajvani U.B., Berg A.H., Lin Y., Jelicks L.A., Laplante M., et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145:367-383.
61. McTernan P.G., McTernan C.L., Chetty R., Jenner K., Fisher F.M., Lauer M.N., et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002, 87:2407.
62. Perseghin G., Lattuada G., De Cobelli F., Ntali G., Esposito A., Burska A., et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006, 91:5122-5125.
63. Montague C.T., Prins J.B., Sanders L., Digby J.E., O'Rahilly S. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997, 46:342-347.
64. Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes Metab 2008, 10:973-993.
65. Flier J.S. Clinical review 94: what's in a name? in search of leptin's physiologic role. J Clin Endocrinol Metab 1998, 83:1407-1413.
66. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001, 104:3052-3056.
67. Soderberg S., Stegmayr B., Stenlund H., Sjostrom L.G., Agren A., Johansson L., et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004, 256:128-136.
68. Wolk R., Berger P., Lennon R.J., Brilakis E.S., Johnson B.D., Somers V.K. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004, 44:1819-1824.
69. Piatti P., Di Mario C., Monti L.D., Fragasso G., Sgura F., Caumo A., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003, 108:2074-2081.
70. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000, 28:1708-1716.
71. Lionetti L., Mollica M.P., Lombardi A., Cavaliere G., Gifuni G., Barletta A. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis 2009, 19:146-152.
72. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993, 91:2463-2469.
73. Norata G.D., Garlaschelli K., Grigore L., Tibolla G., Raselli S., Redaelli L., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009, 19:129-134.
74. Hyogo H., Yamagishi S., Iwamoto K., Arihiro K., Takeuchi M., Sato T., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:1112-1119.
75. Li S.Y., Liu Y., Sigmon V.K., McCort A., Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 2005, 7:448-454.
76. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
77. Basta G., Lazzerini G., Del Turco S., Ratto G.M., Schmidt A.M., De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005, 25:1401-1407.
78. Tikellis C., Thomas M.C., Harcourt B.E., Coughlan M.T., Pete J., Bialkowski K., et al. Cardiac inflammation associated with a western diet is mediated via activation of RAGE by AGEs. Am J Physiol Endocrinol Metab 2008, 295:E323-E330.
79. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
80. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
81. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
82. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006, 91:4628-4634.
83. Lindsey J.B., de Lemos J.A., Cipollone F., Ayers C.R., Rohatgi A., Morrow D.A., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009, 32:1218-1220.
84. Yilmaz Y., Ulukaya E., Gul O.O., Arabul M., Gul C.B., Atug O., et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009, 42:802-807.
85. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
86. Nelson T.L., Vogler G.P., Pedersen N.L., Hong Y., Miles T.P. Genetic and environmental influences on body fat distribution, fasting insulin levels and CVD: are the influences shared?. Twin Res 2000, 3:43-50.
87. Poulsen P., Vaag A., Kyvik K., Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 2001, 44:537-543.
88. Schulz L.O., Bennett P.H., Ravussin E., Kidd J.R., Kidd K.K., Esparza J., et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006, 29:1866-1871.
89. Chandalia M., Abate N., Garg A., Stray-Gundersen J., Grundy S.M. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999, 84:2329-2335.
90. Abate N., Chandalia M., Snell P.G., Grundy S.M. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. J Clin Endocrinol Metab 2004, 89:2750-2755.
91. Hamdy O., Porramatikul S., Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2006, 2:367-373.
92. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
93. Agarwal A.K., Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 2006, 57:297-311.
94. Yang W., Kelly T., He J. Genetic epidemiology of obesity. Epidemiol Rev 2007, 29:49-61.
95. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
96. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25:899-918.
97. Bays H., Dujovne C.A. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006, 8:144-156.
98. Bays H., Blonde L., Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Rev Cardiovasc Ther 2006, 4:871-895.
99. Smas C.M., Sul H.S. Control of adipocyte differentiation. Biochem J 1995, 309(Pt 3):697-710.
100. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
101. Shadid S., Jensen M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003, 26:3148-3152.
102. Resnick H.E., Valsania P., Halter J.B., Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000, 54:596-602.
103. Klein S., Fontana L., Young V.L., Coggan A.R., Kilo C., Patterson B.W., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549-2557.
104. Sjostrom L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.